Early lung cancer marker shows promise:
This article was originally published in Clinica
A peptide in blood or sputum could provide a sensitive marker for the early diagnosis of lung cancer. Magnus von Knebel Doeberitz of the University of Heidelberg in Germany, and colleagues used a reverse transcriptase PCR test to study 175 patients suspected of having lung cancer. They found that preprogastrin-releasing peptide was present in 50% of blood samples and 22% of sputum samples from small-cell lung cancer patients. The blood test also identified 27% of non-small-cell lung cancer patients. The findings appear in the International Journal of Cancer (April).
You may also be interested in...
The Onyx One Clear study, evaluating the Resolute Onyx drug-eluting stent in high bleeding risk patients, met its primary endpoint at the one-year follow up.
Dozens of life science companies are working to find effective treatments for COVID-19. In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into some of the efforts that are under way on this front.
Market researcher The NPD Group identifies the few prestige beauty categories that posted sales growth in the US for the week ending 28 March. Companies that can pivot or ramp up activities in winning segments – and reach consumers digitally while they shelter at home – may fare best during the coronavirus pandemic.